Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 18 studies | 66% ± 15% | |
basal cell | 12 studies | 43% ± 17% | |
oligodendrocyte precursor cell | 11 studies | 44% ± 18% | |
respiratory goblet cell | 8 studies | 43% ± 24% | |
astrocyte | 6 studies | 33% ± 19% | |
club cell | 5 studies | 41% ± 21% | |
Mueller cell | 5 studies | 40% ± 13% | |
deuterosomal cell | 4 studies | 41% ± 14% | |
duct epithelial cell | 4 studies | 37% ± 30% | |
mucus secreting cell | 4 studies | 60% ± 8% | |
epithelial cell | 3 studies | 32% ± 10% | |
secretory cell | 3 studies | 46% ± 18% | |
cardiac muscle cell | 3 studies | 17% ± 2% | |
ependymal cell | 3 studies | 39% ± 13% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 80% | 140.91 | 2119 / 2642 | 92% | 14.28 | 649 / 705 |
pancreas | 100% | 548.26 | 328 / 328 | 63% | 3.06 | 112 / 178 |
liver | 93% | 351.55 | 210 / 226 | 62% | 5.54 | 250 / 406 |
prostate | 97% | 534.22 | 237 / 245 | 51% | 1.88 | 257 / 502 |
kidney | 76% | 131.37 | 68 / 89 | 70% | 5.75 | 635 / 901 |
esophagus | 87% | 185.32 | 1253 / 1445 | 24% | 1.07 | 44 / 183 |
spleen | 100% | 724.95 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.17 | 1 / 1 |
lung | 54% | 404.93 | 310 / 578 | 32% | 2.32 | 375 / 1155 |
bladder | 76% | 167.95 | 16 / 21 | 9% | 0.60 | 43 / 504 |
breast | 56% | 247.32 | 258 / 459 | 23% | 0.73 | 255 / 1118 |
stomach | 72% | 91.47 | 258 / 359 | 6% | 0.22 | 17 / 286 |
intestine | 70% | 204.99 | 678 / 966 | 6% | 0.29 | 29 / 527 |
heart | 69% | 186.59 | 598 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 46% | 1.46 | 37 / 80 |
skin | 4% | 3.09 | 75 / 1809 | 40% | 3.53 | 187 / 472 |
uterus | 14% | 29.74 | 23 / 170 | 19% | 1.20 | 87 / 459 |
ovary | 2% | 1.72 | 3 / 180 | 25% | 1.19 | 108 / 430 |
tonsil | 0% | 0 | 0 / 0 | 20% | 1.43 | 9 / 45 |
adrenal gland | 3% | 4.69 | 9 / 258 | 8% | 0.25 | 19 / 230 |
thymus | 3% | 2.77 | 18 / 653 | 7% | 0.30 | 41 / 605 |
lymph node | 0% | 0 | 0 / 0 | 7% | 0.10 | 2 / 29 |
blood vessel | 3% | 2.21 | 43 / 1335 | 0% | 0 | 0 / 0 |
muscle | 2% | 1.42 | 15 / 803 | 0% | 0 | 0 / 0 |
adipose | 1% | 0.77 | 11 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 1.38 | 3 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030203 | Biological process | glycosaminoglycan metabolic process |
GO_0042446 | Biological process | hormone biosynthetic process |
GO_0030166 | Biological process | proteoglycan biosynthetic process |
GO_0030206 | Biological process | chondroitin sulfate biosynthetic process |
GO_0006790 | Biological process | sulfur compound metabolic process |
GO_0016051 | Biological process | carbohydrate biosynthetic process |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005576 | Cellular component | extracellular region |
GO_0016020 | Cellular component | membrane |
GO_0001537 | Molecular function | N-acetylgalactosamine 4-O-sulfotransferase activity |
GO_0008146 | Molecular function | sulfotransferase activity |
GO_0047756 | Molecular function | chondroitin 4-sulfotransferase activity |
Gene name | CHST9 |
Protein name | Carbohydrate sulfotransferase 9 isoform 2 Carbohydrate sulfotransferase 9 (EC 2.8.2.-) (GalNAc-4-O-sulfotransferase 2) (GalNAc-4-ST2) (GalNAc4ST-2) (N-acetylgalactosamine-4-O-sulfotransferase 2) Alternative protein CHST9 Carbohydrate sulfotransferase (EC 2.8.2.-) |
Synonyms | UNQ2549/PRO6175 |
Description | FUNCTION: Catalyzes the transfer of sulfate to position 4 of non-reducing N-acetylgalactosamine (GalNAc) residues in both N-glycans and O-glycans. Participates in biosynthesis of glycoprotein hormones lutropin and thyrotropin, by mediating sulfation of their carbohydrate structures. Has a higher activity toward carbonic anhydrase VI than toward lutropin. Only active against terminal GalNAcbeta1,GalNAcbeta. Isoform 2, but not isoform 1, is active toward chondroitin. |
Accessions | Q7L1S5 ENST00000618847.5 [Q7L1S5-1] ENST00000580774.2 [Q7L1S5-2] A0A0S2Z5P0 A0A0S2Z5U9 ENST00000581714.5 [Q7L1S5-1] L8EAG4 |